Federal officials are resuming enforcement of regulations that dictate how pharmaceutical products can be advertised to consumers, the Trump administration said on Sept. 9, as President Donald Trump signed a new executive order.
The Food and Drug Administration (FDA) is restarting its enforcement of regulations that prohibit pharmaceutical ads from creating a “misleading impression” and require them to present a “fair balance of information,” a senior administration official told reporters on a call.
The FDA is also reversing its 1997 relaxation of direct-to-consumer ad regulations, which enabled companies to point people to information hosted in other places, such as websites, the official said. Spending on direct-to-consumer ads jumped from $150 million in 1993 to $6 billion in 2016, according to a 2023 paper published in the Journal of Public Economics. The rise primarily happened after the 1997 FDA move….
Trump Signs Order on Direct-to-Consumer Advertising
